(Reuters) -The U.S. Food and Drug Administration has approved Jazz Pharmaceuticals’ combination therapy as a maintenance treatment for adult patients with a type of lung cancer, the regulator said on Thursday.

Shares of the drugmaker were up 1.6% at $139.30 in extended trade.

The drug, Zepzelca, in combination with Roche’s Tecentriq, is approved for patients with extensive-stage small cell lung cancer, whose disease has not progressed after initial chemotherapy.

This is an aggressive form of lung cancer that may spread to other parts of the body including the bone marrow.

Zepzelca is already approved as a second-line treatment — given when the initial treatment fails — for the illness.

The approval is based on late-stage trial data showing a 46% reduction in disease progression and a

See Full Page